Breast Carcinoma malady

Wikipedia: Breast cancer is a type of cancer originating from breast tissue, most commonly from the inner lining of...⁴⁴ more...

MalaCards: Breast Carcinoma, also known as carcinoma of breast nos (disorder), is related to carcinoma and prostatitis. An important gene associated with Breast Carcinoma is BCAS4 (breast carcinoma amplified sequence 4), and among its related pathways are Pancreatic Adenocarcinoma and PAK Pathway. The drugs carmustine and diethylstilbestrol diphosphate and the compounds estrogen and oxygen have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, lymph node and small intestine, and related mouse phenotypes are immune system and nervous system.

Disease Ontology: A breast cancer that derives from breast tissue.⁶

Aliases & Descriptions:

breast carcinoma 6 8 32 43 carcinoma of breast nos (disorder) 6 carcinoma of breast (disorder) 6

carcinoma of breast 6 mammary carcinoma 6 carcinoma 43

Diseases related to breast carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1631)

id	Related Disease	Score	Top Affiliating Genes
1	carcinoma	224.9	ZNF217, ZNF202, PIKFYVE, PIP, PIK3CA, PIK3R1
2	prostatitis	164.3	PIP, PIK3CA, PIK3R1, PIK3CG, LRP1, NCL
3	adenocarcinoma	151.3	ZNF217, PIP, PIK3CA, PIK3R1, PIK3CG, LRP1
4	leukemia	146.8	PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1, SH3GL2
5	pancreatitis	139.8	PIK3CA, PIK3R1, PIK3CG, PI3, LRP1, NCL
6	melanoma	139.6	PIK3CA, PIK3R1, PIK3CG, PI3, LRP1, NCEH1
7	colorectal cancer	137.5	ZNF217, PIK3CA, PIK3R1, PIK3CG, LRPAP1, NCOA3
8	neuronitis	136.7	PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1, SH3GL2
9	hepatocellular carcinoma	131.2	PIK3CA, PIK3R1, PIK3CG, NCL, NCOA3, RECK
10	gastric cancer	128.9	PIK3CA, PIK3R1, PIK3CG, NDC80, NCL, NCOA3
11	esophagitis	127.6	PIK3CA, PIK3CG, NCOA3, RECK, WASL, KIT
12	thyroiditis	125.9	PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1, NCOA2
13	colon cancer	123.0	PIK3CA, PIK3R1, PIK3CG, RECK, CNR2, VWF
14	cervicitis	116.9	ZNF217, PIK3CA, PIK3CG, NCL, RECK, KIT
15	ovarian carcinoma	114.7	PIKFYVE, PIP, PIK3CA, PIK3CG, PI3, NCOA3
16	hypoxia	113.3	ZNF217, PIK3CA, PIK3R1, PIK3CG, LRP1, NCOA2
17	adenoma	110.3	PIK3CA, NCOA2, NCOA3, NCOR1, RECK, KIT
18	sarcoma	105.3	PIK3CA, PIK3R1, PIK3CG, NCOA3, RECK, KIT
19	colon carcinoma	101.4	PIK3CA, PIK3R1, PIK3CG, NCL, KIT, KITLG
20	neuroblastoma	101.4	PIK3CA, PIK3R1, PIK3CG, LRP1, NCL, RECK
21	lung carcinoma	100.0	PIK3CA, PIK3R1, PIK3CG, RECK, SFTPB, PCNA
22	oral squamous cell carcinoma	97.2	PIK3CA, RECK, VTN, SFN, SFRP1, PCNA
23	esophageal squamous cell carcinoma	94.3	PIK3CA, NCOA3, RECK, KIT, KISS1, KISS1R
24	arthritis	93.8	PIK3CG, LRP1, RECK, CNR2, CNTN2, KIT
25	endometrial carcinoma	93.1	PIK3CA, PIK3CG, LRP1, LRPAP1, NCOA3, NCOR1
26	cervical cancer	92.3	ZNF217, PIK3CA, PIK3CG, NCL, VTN, SFN
27	fibrosis	88.2	PIK3CA, PIK3CG, PI3, LRP1, NCOA3, RECK
28	endometrial cancer	87.9	PIK3CA, PIK3R1, PIK3CG, NDC80, NCOA3, KITLG
29	rheumatoid arthritis	87.0	PIK3CG, LRP1, RECK, CNR2, CNTN2, KIT
30	myeloma	86.6	PIK3CA, PIK3R1, PIK3CG, LRP1, RECK, CNTN2
31	myeloid leukemia	86.4	PIK3CA, PIK3R1, PIK3CG, NCL, NCOA2, NCOA3
32	nasopharyngitis	86.1	PIK3CA, PIK3CG, NCOA3, RECK, KIT, KITLG
33	hepatitis b	86.0	PIK3CA, PIK3R1, PIK3CG, CNTN2, KIF1B, KITLG
34	thyroid carcinoma	85.5	PIK3CA, PIK3CG, PI3, KIF1B, KITLG, SFN
35	cholesterol	85.3	ZNF202, PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1
36	alzheimer's disease	84.2	PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1, NCL
37	osteosarcoma	84.1	PIK3CA, PIK3CG, RECK, KIT, VWF, VTN
38	retinitis	82.5	PIK3CA, PIK3CG, LRP1, LRPAP1, CNGB1, CNR2
39	laryngitis	81.8	PIK3CA, SH3GL2, SFN, PCNA, BTG2, RB1
40	retinoblastoma	81.3	PIK3CA, PIK3R1, PIK3CG, NDC80, NCL, RECK
41	astrocytoma	81.1	PIK3CA, PIK3R1, PIK3CG, LRP1, RECK, CNR2
42	renal cell carcinoma	78.7	PIK3CA, KIT, KISS1, KISS1R, SFRP1, PCNA
43	cholangiocarcinoma	77.1	PIK3CA, PIK3CG, RECK, KIT, SFN, PCNA
44	pancreatic carcinoma	76.9	PIK3CA, KITLG, VTN, PCNA, RB1, RBBP8
45	lymphocytic leukemia	76.3	PIK3CA, PIK3CG, NCL, RECK, CNTN2, KIT
46	epithelial ovarian cancer	76.2	PIK3CA, PIK3CG, NCOA3, NCOR1, KISS1, KISS1R
47	cervical carcinoma	76.1	PIK3CA, PIK3CG, RECK, KIT, KITLG, VTN
48	cerebritis	76.0	PIK3R1, PIK3CG, LRP1, CNTN2, KITLG, VWF
49	multiple myeloma	74.6	PIK3CA, PIK3R1, PIK3CG, LRP1, RECK, KIT
50	bladder carcinoma	73.5	PIK3CA, PIK3CG, SFN, PCNA, RB1, SELE

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 carmustine, diethylstilbestrol, diethylstilbestrol diphosphate, nilutamide

MalaCards organs/tissues related to breast carcinoma:

²²

MGI Mouse Phenotypes related to breast carcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system phenotype	MP:0005387	44.3	LRP1, NCEH1, NCOA2, NCOA3, NCOR1, CNR2
2	nervous system phenotype	MP:0003631	42.4	LRP1, LRPAP1, NCOR1, RECK, CNGB1, CNTN2
3	tumorigenesis	MP:0002006	39.6	PIK3CA, PIK3R1, NCOA3, KIT, KITLG, SFN
4	integument phenotype	MP:0010771	38.4	PIK3CG, NCOA2, NCOA3, NCOR1, RECK, CNR2
5	skeleton phenotype	MP:0005390	37.8	PIK3CG, LRP1, RECK, KIT, KIF1B, KITLG
6	behavior/neurological phenotype	MP:0005386	37.1	PIK3CA, LRP1, NCOA2, NCOA3, NCOR1, CNTN2
7	embryogenesis phenotype	MP:0005380	36.8	PIKFYVE, PIK3CA, NCOA2, NCOA3, NCOR1, RECK
8	digestive/alimentary phenotype	MP:0005381	36.4	NCOA3, WASL, KIT, KISS1, KITLG, KISS1R
9	normal phenotype	MP:0002873	36.1	PIK3R1, LRP1, LRPAP1, WASL, KISS1R, VTN
10	hematopoietic system phenotype	MP:0005397	35.4	KIT, KISS1R, SFN, SFRP1, PCGF2, PCNA
11	vision/eye phenotype	MP:0005391	32.3	PIK3CA, CNGB1, KIT, KITLG, SFN, PCGF2
12	renal/urinary system phenotype	MP:0005367	27.0	LRPAP1, NCOA3, KIT, KISS1, KISS1R, SFRP4
13	limbs/digits/tail phenotype	MP:0005371	25.8	RECK, KIT, KITLG, SFN, SFRP1, PCGF2
14	no phenotypic analysis	MP:0003012	22.3	PIK3R1, NCOA2, SFRP1, PCNA, BUB1, RB1
15	endocrine/exocrine gland phenotype	MP:0005379	21.9	LRPAP1, NCOA2, WASL, KISS1, KISS1R, SFN
16	hearing/vestibular/ear phenotype	MP:0005377	21.4	NCOA3, KIT, KITLG, SFN, RB1, RBP1
17	craniofacial phenotype	MP:0005382	20.9	NCOA3, KIT, KITLG, PCGF2, NBN, LPAR1
18	adipose tissue phenotype	MP:0005375	20.6	PIK3CA, PIK3R1, LRP1, NCOA3, NCOR1, SFRP1
19	pigmentation phenotype	MP:0001186	17.3	KIT, KITLG, RB1, RBP1, VLDLR, BRAF
20	other phenotype	MP:0005395	15.5	LRPAP1, RECK, BUB1, SERPINH1, RARG, RARA
21	growth/size phenotype	MP:0005378	INF	PIK3CA, PIK3R1, PIK3CG, LRP1, NCOA2, NCOA3
22	mortality/aging	MP:0010768	INF	PIKFYVE, PIK3CA, LRP1, LRPAP1, NCOR1, RECK
23	respiratory system phenotype	MP:0005388	INF	KIF1B, SFRP4, SELP, BRCA1, LPAR2, MYCN
24	cardiovascular system phenotype	MP:0005385	INF	PIK3CA, PIK3R1, PIK3CG, LRP1, NCEH1, RECK
25	reproductive system phenotype	MP:0005389	INF	PIK3CA, LRPAP1, NCOA2, NCOA3, KISS1, KISS1R
26	muscle phenotype	MP:0005369	INF	PIK3CA, PIK3R1, PIK3CG, LRP1, NCOA3, NCOR1
27	cellular phenotype	MP:0005384	INF	PIKFYVE, PIK3CA, PIK3R1, PIK3CG, NCEH1, NCOA3
28	liver/biliary system phenotype	MP:0005370	INF	NCOA3, NCOR1, RECK, KIT, SFN, BUB1
29	homeostasis/metabolism phenotype	MP:0005376	INF	PIKFYVE, PIK3CA, PIK3R1, PIK3CG, LRP1, LRPAP1

Articles related to breast carcinoma:

(show top 50)    (show all 2361)

id	Title	Authors	Year	Affiliating Genes
1	CTEN (C-terminal tensin-like), a novel oncogene overe xpressed in invasive breast carcinoma of poor prognosis. (20390342)	Albasri A.... Green A.R.	2011	TNS4
2	Effects of human mesenchymal stem cells on ER-positiv e human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. (21087507)	Rhodes L.V.... Burow M.E.	2010	CXCL12
3	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. (20614180)	Joosse S.A.... Nederlof P.M.	2010	BRCA2
4	Sporadic breast carcinomas with somatic BRCA1 gene de letions share genotype/phenotype features with familial breast carcinomas. (20944121)	Rhiem K.... Schmutzler R.K.	2010	BRCA1
5	Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization. (20670419)	Vogel U.F.	2010	ERBB2
6	Expression and mutational analysis of GATA3 in Malays ian breast carcinomas. (21329183)	Bong P.N.... Syed Hussain S.N.	2010	GATA3
7	BRMS1 expression alters the ultrastructural, biomecha nical and biochemical properties of MDA-MB-435 human breast carcinoma cells: an AFM and Raman microspectroscopy study. (20083343)	Wu Y.... Zhou A.	2010	BRMS1
8	CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts expos ed to factors secreted by breast cancer cells. (19584257)	Eck S.M.... Brinckerhoff C.E.	2009	CXCR4, MMP1
9	Immunohistochemical detection of estrogen receptor, p rogesterone receptor, and human epidermal growth factor receptor 2 expression i n breast carcinomas: comparison on cell block, needle-core, and tissue block pr eparations. (19551847)	Hanley K.Z.... Siddiqui M.T.	2009	ERBB2, ESR1
10	Immunohistochemical heterogeneity of breast carcinoma s negative for estrogen receptors, progesterone receptors and Her2/neu (basal-l ike breast carcinomas). (18654595)	Rakha E.A.... Reis-Filho J.S.	2008	PGR
11	Mitochondria-mediated apoptosis in human breast carcinoma MCF-7 cells induced by a novel selenadiazole derivative. (18222058)	Chen T.... Yang F.	2008	BCL2, CASP8, CASP9
12	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. (18782450)	Herschkowitz J.I.... Perou C.M.	2008	RB1
13	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). (17885672)	Lerma E.... Barnadas A.	2007	KIT, PGR, ESR1
14	Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. (17359284)	Suzuki T.... Sasano H.	2007	MYC, PLK1, CCNB1
15	Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. (17129704)	Mylona E.... Nakopoulou L.	2007	FLT4, VEGFC, FIGF
16	A case report of remote cutaneous metastasis from male breast carcinoma. (17614806)	Ai-Ping F.... Yan W.	2007	PSEN2, CHKA, FUCA2
17	The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas. (17593058)	Frederik P.... Tjalma W.A.	2007	PGR
18	Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. (17760952)	Muto M.... Unno M.	2007	SLCO1B3
19	Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. (17709312)	Kleinberg L.... Davidson B.	2007	BIRC5, XIAP, BIRC7
20	Expression and significance of TRAF4 protein in breast carcinoma (17927880)	Dai W.B.... Yan J.	2007	TRAF4, TNFRSF4
21	A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells. (15868899)	Akahane M.... Thorgeirsson U.P.	2005	KDR, CCNA2, FIGF
22	The effect of neoadjuvant chemotherapy on estrogen a nd progesterone receptor expression in breast carcinoma (16194363)	Wang S.... Liu H.J.	2005	PGR, ESR1
23	HER2 expression and its prognostic implication in ly mph node negative breast carcinoma: a Meta-analysis (15938823)	Guo H.... Zhou Y.	2005	ERBB2
24	Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells. (15256436)	Chung J.... Mercurio A.M.	2004	PRKCA, VEGFA
25	p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. (15619212)	Singh M.... Robinson W.A.	2004	ESR1, CDKN2A
26	Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. (14517343)	Furger K.A.... Tuck A.B.	2003	SPP1, ITGB3
27	Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. (12529794)	Wirtz P.W.... Verschuuren J.J.	2002	NOVA1
28	Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. (12450792)	Tognon C.... Sorensen P.H.	2002	NTRK3, ETV6
29	Fas ligand expression in BRCA1-associated hereditary breast carcinoma clearly differs from that in sporadic breast carcinoma. (11437105)	Ito Y.... Matsuura N.	2001	FAS
30	Pancreatic tumor: an unusual presentation of an occult breast carcinoma (11873667)	Odzak A.... Frider B.	2001	MUC1, CEACAM3, KRT20
31	Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule. (11127919)	Santeusanio G.... Spagnoli L.G.	2000	ESR1
32	Cytokines facilitate chemotactic motility of breast carcinoma cells. (11029802)	Arihiro K.... Inai K.	2000	HGF, IL8
33	Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. (11029509)	Kannan K.... Shanmugam G.	2000	TP53, FHIT
34	Comparative evaluation by semiquantitative reverse tr anscriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. (9514046)	Lacave R.... Bernaudin J.F.	1998	ABCC1, ABCB1
35	Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. (9583721)	Sierra A.... Fabra A.	1998	BCL2L1, BAK1
36	Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. (9655297)	Querzoli P.... Nenci I.	1998	ESR1
37	Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. (9037310)	Kapucuoglu N.... Eusebi V.	1997	BCL2, BAX
38	nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients. (9070493)	Russell R.L.... Kute T.E.	1997	CTSD, NME1
39	Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. (9164678)	Burak W.E.... Brueggemeier R.W.	1997	TFF1
40	Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. (9815631)	Zhang G.J.... Tsuchiya A.	1997	BCL2
41	Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line. (8774705)	Faggioli L.... Palmieri M.	1996	IL6, IL1B, CEBPB
42	Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. (7749141)	O'Donoghue A.E.... Ellis I.O.	1995	CTSD
43	Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. (7543702)	Holmes F.A.	1995	CSF3
44	Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. (7981902)	Haerslev T.... Jacobsen G.K.	1994	PGR, PCNA
45	Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. (8346178)	Visscher D.W.... Crissman J.D.	1993	CTSD, PLAU
46	Immunohistologic analysis of invasive phenotype in breast carcinoma. A clinicopathologic study. (8302708)	Visscher D.W.... Crissman J.	1993	CTSD
47	Estrogen receptor imaging with 17 alpha-[123I]iodovin yl-11 beta-methoxyestradiol (MIVE2)--Part II. Preliminary results in patients w ith breast carcinoma. (1629015)	Ribeiro-Barras M.J.... Besnard J.C.	1992	ESR1
48	In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. (1751397)	Prost-Avallet O.... Adessi G.L.	1991	STS, ARSH
49	Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. (1988702)	Thor A.... Weber L.A.	1991	PSEN2, HSPB1
50	Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. (1701960)	Domagala W.... Osborn M.	1990	VIM, NOS2

Genes related to breast carcinoma according to GeneCards:

(show top 50)    (show all 1099)

id	Symbol	Description	Score	GeneCards Section Context
1	BCAS4	breast carcinoma amplified sequence 4	11.0	Transcripts, Proteins, Aliases & Descriptions, Orthologs
2	BCAS3	breast carcinoma amplified sequence 3	11.0	Transcripts, Aliases & Descriptions, Proteins, Orthologs
3	KISS1	KiSS-1 metastasis-suppressor	11.0	Publications, Summaries
4	SNAI2	snail homolog 2 (Drosophila)	11.0	Publications, Summaries
5	NTRK3	neurotrophic tyrosine kinase, receptor, type 3	11.0	Publications, Summaries
6	SYK	spleen tyrosine kinase	11.0	Publications, Summaries
7	BCAS1	breast carcinoma amplified sequence 1	11.0	Transcripts, Publications, Aliases & Descriptions, Proteins (show all 5 sections) Orthologs
8	BCAS2	breast carcinoma amplified sequence 2	11.0	Transcripts, Functions, Aliases & Descriptions, Orthologs
9	CTSL2	cathepsin L2	11.0	Summaries
10	MUC1	mucin 1, cell surface associated	11.0	Publications, Aliases & Descriptions
11	BCAS2P1	breast carcinoma amplified sequence 2 pseudogene 1	11.0	Aliases & Descriptions
12	BCAS2P2	breast carcinoma amplified sequence 2 pseudogene 2	11.0	Aliases & Descriptions
13	BCAS2P3	breast carcinoma amplified sequence 2 pseudogene 3	11.0	Aliases & Descriptions
14	MBOAT7	membrane bound O-acyltransferase domain containing 7	11.0	Publications, Aliases & Descriptions
15	ARID4B	AT rich interactive domain 4B (RBP1-like)	11.0	Publications, Aliases & Descriptions
16	ST18	suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)	11.0	Transcripts, Aliases & Descriptions, Orthologs
17	BRMS1L	breast cancer metastasis-suppressor 1-like	11.0	Summaries
18	IKBKE	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon	11.0	Summaries
19	RPL13	ribosomal protein L13	11.0	Summaries
20	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	11.0	Publications
21	PGR	progesterone receptor	11.0	Publications
22	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0	Publications
23	ESR1	estrogen receptor 1	11.0	Publications
24	BRCA1	breast cancer 1, early onset	11.0	Publications
25	TP53	tumor protein p53	11.0	Publications
26	TFF1	trefoil factor 1	11.0	Publications
27	CTSD	cathepsin D	11.0	Publications
28	NME1	NME/NM23 nucleoside diphosphate kinase 1	11.0	Publications
29	KRT19	keratin 19	11.0	Publications
30	BRCA2	breast cancer 2, early onset	11.0	Publications
31	CD44	CD44 molecule (Indian blood group)	11.0	Publications
32	MET	met proto-oncogene (hepatocyte growth factor receptor)	11.0	Publications
33	VEGFC	vascular endothelial growth factor C	11.0	Publications
34	MDM2	Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse)	11.0	Publications
35	PIP	prolactin-induced protein	11.0	Publications
36	CDH3	cadherin 3, type 1, P-cadherin (placental)	11.0	Publications
37	CHGB	chromogranin B (secretogranin 1)	11.0	Publications
38	FIGF	c-fos induced growth factor (vascular endothelial growth factor D)	11.0	Publications
39	KRT14	keratin 14	11.0	Publications
40	KRT8	keratin 8	11.0	Publications
41	ST3GAL6	ST3 beta-galactoside alpha-2,3-sialyltransferase 6	11.0	Publications
42	BCL2	B-cell CLL/lymphoma 2	11.0	Publications
43	CYP19A1	cytochrome P450, family 19, subfamily A, polypeptide 1	11.0	Publications
44	MKI67	antigen identified by monoclonal antibody Ki-67	11.0	Publications
45	PCNA	proliferating cell nuclear antigen	11.0	Publications
46	PLAU	plasminogen activator, urokinase	11.0	Publications
47	PLAUR	plasminogen activator, urokinase receptor	11.0	Publications
48	THBS1	thrombospondin 1	11.0	Publications
49	TOP2A	topoisomerase (DNA) II alpha 170kDa	11.0	Publications
50	BLZF1	basic leucine zipper nuclear factor 1	11.0	Publications

Pathways related to breast carcinoma according to GeneDecks:

(show top 50)    (show all 303)

id	Pathway	Score	Top Affiliating Genes
1	Pancreatic Adenocarcinoma36	24.7	PIK3R1, KIT, KITLG, BTC, RB1, BRAF
2	PAK Pathway36	21.1	PIP, PIK3R1, KIT, KITLG, BTC, VEGFB
3	TGF-Beta Pathway36	20.2	PIK3R1, KITLG, BTC, VEGFB, VEGFC, BMP2
4	Phospholipase-C Pathway36	20.1	KIT, KITLG, BTC, VEGFB, VEGFC, BMP2
5	p53 Mediated Apoptosis36	19.8	PIK3R1, KIT, KITLG, BTC, VEGFB, VEGFC
6	p70S6K Signaling36	19.4	PIK3R1, KIT, KITLG, BTC, VEGFB, VEGFC
7	Nanog in Mammalian ESC Pluripotency36	19.3	KIT, KITLG, BTC, BRAF, VEGFB, VEGFC
8	eNOS Signaling36	18.4	PIK3R1, CNGB1, KIT, KITLG, BTC, BMP2
9	ErbB signaling pathway20	16.2	PIK3CA, PIK3R1, PIK3CG, BTC, BRAF, MYC
10	Actin Nucleation by ARP-WASP Complex36	15.9	WASL, KIT, RAC1, KDR, MST1R, CDC42
11	p53 signaling pathway20	15.8	SFN, SERPINB5, SERPINE1, BID, CHEK1, CHEK2
12	Small cell lung cancer20	15.7	PIK3CA, PIK3R1, PIK3CG, RB1, MYC, RARB
13	Development_EGFR signaling pathway41	15.5	PIK3CA, PIK3R1, BTC, MYC, RAF1, RAC1
14	Regulation of actin cytoskeleton20	15.4	PIKFYVE, PIK3R1, WASL, BRAF, VCL, RAF1
15	Neurotrophin signaling pathway20	15.0	PIK3CA, PIK3CG, BRAF, RAF1, RAC1, RAPGEF1
16	Signal transduction_AKT signaling41	14.9	PIK3CA, PIK3R1, PCNA, MYC, BCL2L1, BAD
17	Toxoplasmosis20	14.7	PIK3CA, PIK3R1, PIK3CG, BCL2, BCL2L1, BAD
18	Transcription Androgen Receptor nuclear signaling10	14.7	NCOA2, NCOR1, RAF1, FZD7, CDKN1A, MMP2
19	Bladder cancer20	14.7	RB1, BRAF, VEGFA, VEGFB, VEGFC, MYC
20	Hepatitis C20	14.7	PIK3CA, PIK3R1, PIK3CG, BRAF, RAF1, CLDN2
21	Translation_Non-genomic (rapid) action of Androgen Receptor41	14.6	PIK3CA, PIK3R1, RAF1, MTOR, FZD7, FOXO3
22	Adherens junction20	14.3	WASL, VCL, RAC1, FYN, CDC42, CDH1
23	TNF Superfamily Pathway36	14.2	PIK3R1, JUN, FOS, MAPK8, MAP3K7, MAP2K6
24	Development_FGFR signaling pathway41	14.1	PIK3CA, PIK3R1, RAF1, RAC1, PAK1, SDC1
25	PEDF Induced Signaling36	14.1	PIP, BRAF, BMP2, BMP6, BMP7, RAF1
26	Non-small cell lung cancer20	14.0	PIK3CA, PIK3R1, PIK3CG, RB1, BRAF, RAF1
27	Development_Thrombopoietin-regulated cell processes41	14.0	PIK3CA, PIK3R1, BRAF, MYC, RAF1, RAC1
28	ErbB Family Pathway36	13.9	PIK3R1, BTC, BRAF, RAF1, PAK1, JUN
29	Development Flt3 signaling10	13.8	PIK3CA, PIK3R1, RAF1, RAC1, PAK1, BCL2L1
30	Immune response_IFN gamma signaling pathway41	13.8	PIK3CA, PIK3R1, BRCA1, MYC, RAPGEF1, CEBPB
31	Development_Neurotrophin family signaling41	13.8	PIK3CA, PIK3R1, BRAF, RAF1, RAC1, RAPGEF1
32	Immune response Oncostatin M signaling via MAPK in human cells10	13.8	RAF1, RAC1, CEBPB, JUN, MMP1, MMP13
33	Development HGF signaling pathway10	13.7	PIK3CA, PIK3R1, RAF1, RAC1, RAPGEF1, SDC1
34	Apoptosis Signaling Pathways37	13.7	SFN, BID, BIRC5, BIRC7, BCL2, BCL2L1
35	14-3-3 Induced Apoptosis36	13.5	PIK3R1, BID, BCL2, BAD, JUN, FOS
36	RAR-Gamma-RXR-Alpha Degradation36	13.5	PIP, BMP2, BMP7, RARG, LIF, IL11
37	Immune response_IL-2 activation and signaling pathway41	13.5	PIK3CA, PIK3R1, MYC, RAF1, CISH, JUN
38	Development ERBB-family signaling10	13.4	PIK3R1, BTC, MYC, RAF1, AREG, GRB7
39	Chagas disease (American trypanosomiasis)20	13.3	PIK3CA, PIK3R1, PIK3CG, SERPINE1, JUN, CD247
40	Amoebiasis20	13.3	PIK3CA, PIK3R1, SERPINB3, SERPINB2, VCL, MUC2
41	TRAF Pathway36	13.1	PIK3R1, JUN, FOS, IL12A, IL1A, IL1B
42	Development EPO-induced MAPK pathway10	13.1	PIK3CG, KIT, KITLG, RAF1, RAC1, RAPGEF1
43	IL-2 Pathway36	13.1	PIK3R1, MYC, RAF1, JUN, FOS, IL2
44	Development_Growth hormone signaling via PI3K/AKT and MAPK cascades41	13.0	PIK3R1, CEBPB, JUN, JAK2, FOS, IRS1
45	Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR210	12.7	MYC, RAF1, BCL2, BAX, JUN, FOS
46	Development_PDGF signaling via MAPK cascades41	12.7	PIK3CA, PIK3R1, RAF1, RAC1, JUN, ITPR1
47	ErbB2-ErbB3 Heterodimers36	12.4	PIK3R1, RAF1, BAD, ITPR1, FOXO3, MAP2K6
48	HMGB1 Pathway36	12.2	PIK3R1, RAC1, JUN, CDC42, FOS, IL1A
49	Apoptosis and survival_Caspase cascade41	12.2	LMNA, LMNB1, BID, PARP1, BAX, XIAP
50	Translation Regulation activity of EIF4F10	11.1	PAK1, AKT2, PDPK1, TIAM1, SOS1

Compounds related to breast carcinoma according to GeneDecks:

(show top 50)    (show all 475)

id	Compound	Score	Top Affiliating Genes
1	estrogen32	53.1	PIP, PIK3R1, NCL, NCOA2, NCOA3, NCOR1
2	oxygen32 18	41.1	PI3, CNTN2, KITLG, SFTPB, RB1, SELPLG
3	glutamate32	32.6	PIK3CA, PIK3R1, CNGB1, CNR2, CNTN2, VTN
4	actinomycin d32	31.8	PIK3CA, PIK3CG, NCL, KIT, KITLG, SFTPB
5	butyrate32	28.7	NCOA3, KITLG, PCNA, RB1, SETD2, VIM
6	5fluorouracil32	27.1	PIK3CA, PIK3CG, KIT, KITLG, PCNA, RB1
7	tgf beta132	21.6	LRP1, KITLG, SETD2, SERPINE1, VCAN, BMP6
8	n acetylcysteine32	21.1	VWF, PCNA, GCLC, SELE, SELP, SETD2
9	iron32 18	21.8	RECK, KITLG, SETD2, SERPINA1, SERPINA3, VIM
10	rapamycin32 42	21.2	PIK3CG, KIT, KITLG, RB1, NBN, VIM
11	dopamine32 9 18 9	22.5	PIK3CA, SELE, SERPINA3, MYCN, BMP2, BMP6
12	p00232	19.2	KIT, RB1, SERPINB5, BRAF, BRCA1, BRCA2
13	lysine32	18.9	NCL, NCOA2, RECK, CNTN2, SERPINB2, SERPINA1
14	phorbol32	18.3	SERPINB2, MYC, MYB, RAF1, RAC1, CHGA
15	geldanamycin32 9 9	20.0	PIK3R1, PIK3CG, SETD2, BRAF, VEGFA, VCL
16	aspirin32 34 18	18.8	KITLG, VWF, VTN, PCNA, SELE, SELP
17	norepinephrine32 9 18 9	19.7	KITLG, VWF, SELE, SELP, BMP6, LIF
18	latex32	16.6	CNTN2, WASL, KITLG, VWF, VTN, SELPLG
19	tetracycline32 9 9	18.5	CNTN2, VWF, RB1, MYCN, BMP2, RAC1
20	p00332	15.7	KIT, RB1, SERPINA1, SERPINE1, BRCA1, BRCA2
21	phosphatidylcholine32	15.6	SFTPB, SELE, VIM, RAF1, RAC1, LIPE
22	vitamin a32 9 18 9	18.5	VWF, SFTPB, RB1, RBP1, SERPINA1, SERPINA3
23	caffeine32 34 9 18 9	19.5	PIK3R1, PCNA, NAT2, BRCA1, VDR, BMP6
24	chloride32	15.4	RECK, BLVRB, CLU, CLIC1, CLNS1A, MUC5AC
25	glycosaminoglycan32	15.4	LRP1, VTN, VCAN, BMP2, CD36, CD44
26	sialic acid32	15.2	RECK, SELPLG, SERPINA3, CLU, LGALS1, MUC2
27	sulforaphane32	14.9	PIK3CG, RB1, PARP1, KEAP1, JUN, CDKN1A
28	4-hydroxynonenal32 18	15.9	GCLC, MYC, MYB, PARP1, CHKA, BAX
29	nifedipine32 9 9	16.9	PIK3CG, SELE, SERPINE1, BMP2, BMP6, BGLAP
30	ibmx32	14.8	SFTPB, BMP2, RARB, RAF1, CGA, CDK2
31	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	14.4	PCNA, MYC, PARP1, BCL2, BCL2L1, BAK1
32	hydroxyapatite32	14.3	KITLG, VTN, VIM, VCL, BMP2, BMP7
33	fulvestrant32 34 9 9	17.0	PIK3CG, PCNA, AR, MAPK10, MAPK1, IGFBP3
34	thyroxine32 18	14.8	VWF, PCNA, SERPINA3, VDR, BGLAP, LEP
35	sulindac32 9 9	15.7	PCNA, BIRC5, BCL2, BCL2L1, BAX, XIAP
36	phenethyl isothiocyanate32	13.3	MYC, BID, PARP1, BCL2, BCL2L1, BAX
37	melphalan32 9 9	15.2	GCLC, RAD51, BIRC5, BCL2L1, CHKB, MVP
38	2-deoxyglucose32	13.1	PIK3R1, PIK3CG, LIPE, XBP1, FOS, IRS1
39	triiodothyronine32	13.1	NCOA2, NCOR1, RARA, LEP, LEPR, CHKB
40	mnng32	12.9	PCNA, PARP1, CHEK1, CHEK2, MUC5AC, XRCC1
41	phenylephrine32 9 18 9	15.6	RAF1, RAC1, LIF, LEP, CGA, AR
42	titanium32	12.6	VTN, VIM, VCL, BMP2, BMP7, BGLAP
43	octreotide32 42 9 9	15.1	VEGFA, CHGA, MPO, MME, MMP2, MKI67
44	apocynin32	12.0	SELE, SETD2, RAC1, MPO, JUN, JAK2
45	ritonavir32 34 9 9	14.1	CD36, IRS1, INS, IL4, APOA1, APOE
46	polyinosinic-polycytidylic acid32	11.0	SELE, CD83, CD40, IRF1, IL18, IL2
47	ribavirin32 34 9 9	13.8	VIPR1, LEP, CD40LG, MMP1, MMP2, MMP9
48	serine32	INF	PIKFYVE, PIK3CA, PIK3R1, PIK3CG, PI3, LRP1
49	lactate32	INF	PIK3CA, RECK, KIT, KITLG, VWF, VTN
50	tyrosine32	INF	PIKFYVE, PIK3CA, PIK3R1, PIK3CG, PI3, LRP1

Cellular components related to breast carcinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:005737	49.7	PIK3CG, LRP1, SH3GL2, NCOA3, WASL, KIT
2	plasma membrane	GO:005886	40.1	PIK3R1, PIK3CG, LRPAP1, SH3GL2, RECK, CNR2
3	cytosol	GO:005829	39.0	PIKFYVE, PIK3CA, PIK3R1, PIK3CG, SH3GL2, NDC80
4	extracellular region	GO:005576	32.2	PIP, LRPAP1, KISS1, KIAA0100, KITLG, VWF
5	nucleoplasm	GO:005654	27.4	ZNF217, NCOA2, NCOA3, NCOR1, RCC1, PCNA
6	extracellular space	GO:005615	26.4	KIT, KITLG, VTN, SFN, SFRP1, SFRP4
7	integral to plasma membrane	GO:005887	22.2	LRP1, CNR2, CNTN2, SELP, SELPLG, VIPR1
8	cell surface	GO:009986	19.1	LRPAP1, CNTN2, KISS1R, SFRP1, SFRP4, VLDLR
9	perinuclear region of cytoplasm	GO:048471	17.9	PIKFYVE, BUB1B, SELE, VLDLR, LMNA, RAD51
10	extracellular matrix	GO:031012	14.7	VWF, VTN, SFRP1, SERPINE1, VCAN, CLU
11	focal adhesion	GO:005925	14.4	BRCA1, VCL, LIMD1, LIMA1, PAK1, KEAP1
12	external side of plasma membrane	GO:009897	13.7	KIT, VWF, SELP, KDR, KCNJ3, S1PR1
13	platelet alpha granule lumen	GO:031093	12.3	VWF, SERPINA1, SERPINE1, VEGFA, VEGFB, VEGFC
14	membrane raft	GO:045121	12.0	PIKFYVE, SELE, BSG, SDC4, FURIN, JAK2
15	nucleus	GO:005634	INF	ZNF202, LRP1, NDC80, NCL, NCOA2, NCOA3

Biological processes related to breast carcinoma according to GeneDecks:

(show top 50)    (show all 70)

id	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:007165	26.6	SH3GL2, KIT, KITLG, SFN, VLDLR, VEGFC
2	apoptotic process	GO:006915	24.0	KIF1B, SFN, BUB1, BUB1B, RBM5, NBN
3	positive regulation of cell proliferation	GO:008284	22.9	KIT, SFRP1, BTC, NBN, VIPR1, VEGFA
4	positive regulation of transcription from RNA polymerase II promoter	GO:045944	20.8	NCOA2, NCOA3, RB1, SERPINE1, BRCA1, VEGFA
5	blood coagulation	GO:007596	20.4	PIK3CA, PIK3R1, PIK3CG, VWF, SELP, SELPLG
6	negative regulation of apoptotic process	GO:043066	19.8	PIK3CG, SFRP1, PCGF2, BTC, BTG2, RB1CC1
7	angiogenesis	GO:001525	19.1	PIK3CA, PIK3CG, NCL, SETD2, SERPINE1, VEGFA
8	cell proliferation	GO:008283	19.0	KITLG, SFN, PCNA, BUB1, BUB1B, NBN
9	response to drug	GO:042493	19.0	SFRP1, NBN, VLDLR, VEGFC, MYC, LIPE
10	positive regulation of transcription, DNA-dependent	GO:045893	18.9	NCOA3, SFRP1, RB1, SEC14L2, BRCA1, BRCA2
11	cell adhesion	GO:007155	18.2	CNTN2, KITLG, VWF, VTN, SELP, SELPLG
12	virus-host interaction	GO:019048	17.8	PIK3R1, VRK2, BUB1, RB1, VIM, BIN1
13	positive regulation of cell migration	GO:030335	16.4	VEGFA, BMP2, KDR, S1PR1, CGA, FURIN
14	innate immune response	GO:045087	16.1	PIK3CG, CLU, BCL2, BCL2L1, LGALS3, S100A7
15	protein autophosphorylation	GO:046777	16.1	KIT, VRK2, PAK1, KDR, CHEK2, MTOR
16	platelet activation	GO:030168	16.0	PIK3CA, PIK3R1, PIK3CG, VWF, SELP, SERPINA1
17	cell cycle arrest	GO:007050	15.4	RB1, NBN, VASH1, MYC, RASSF1, BARD1
18	inflammatory response	GO:006954	15.0	PIK3CG, CNR2, KIT, SELE, SELP, SERPINA3
19	positive regulation of gene expression	GO:010628	14.9	NCOA3, KIT, SFRP4, BRAF, VEGFA, VDR
20	anti-apoptosis	GO:006916	14.9	PIK3CA, GCLC, SERPINB2, BRAF, VHL, VEGFB
21	fibroblast growth factor receptor signaling pathway	GO:008543	14.9	PIK3CA, PIK3R1, BRAF, RAF1, BAD, MTOR
22	nerve growth factor receptor signaling pathway	GO:048011	14.8	PIK3CA, PIK3R1, SH3GL2, BRAF, RAF1, RAC1
23	response to estradiol stimulus	GO:032355	14.8	SFRP4, SERPINA1, BRCA2, VDR, RARA, BID
24	insulin receptor signaling pathway	GO:008286	14.8	PIK3CA, PIK3R1, RAF1, MTOR, CDK1, IRS1
25	regulation of cell proliferation	GO:042127	14.7	KIT, SERPINE1, BRCA1, BID, BIRC7, SCGB3A1
26	induction of apoptosis	GO:006917	14.7	BOK, BAD, BAX, LALBA, CEBPB, CDKN1B
27	response to hypoxia	GO:001666	14.6	SFTPB, SERPINA1, VEGFA, BMP2, RAF1, LIMD1
28	phosphatidylinositol-mediated signaling	GO:048015	14.5	PIK3CA, PIK3R1, NDC80, PCNA, BUB1B, BAD
29	leukocyte migration	GO:050900	14.3	PIK3CA, PIK3R1, SELP, SELPLG, BSG, MSN
30	cell-cell signaling	GO:007267	14.3	BMP2, LALBA, CGA, CGB, CD86, ITGB2
31	positive regulation of endothelial cell proliferation	GO:001938	14.3	VEGFA, VEGFB, BMP2, BMP6, KDR, MTOR
32	activation of MAPK activity	GO:000187	14.3	KIT, LPAR1, LPAR2, S1PR2, CDK1, INSR
33	positive regulation of protein phosphorylation	GO:001934	14.1	RB1CC1, VEGFA, BMP2, MTOR, CD40, ITGB3
34	response to lipopolysaccharide	GO:032496	14.0	CNR2, SFTPB, SELE, SELP, SERPINA1, S100A7
35	aging	GO:007568	13.9	VDR, BAK1, FURIN, JUN, GSN, IL1B
36	positive regulation of MAPK cascade	GO:043410	13.8	KIT, LPAR1, LPAR2, LIF, KDR, LEP
37	female pregnancy	GO:007565	13.8	LIPE, CLDN4, BCL2, SCGB1A1, LEP, IRF1
38	positive regulation of cell division	GO:051781	13.6	BTC, VEGFA, VEGFB, VEGFC, YBX1, FIGF
39	platelet degranulation	GO:002576	13.5	VWF, SELP, SERPINA1, SERPINE1, VEGFA, VEGFB
40	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	13.3	KITLG, VTN, VEGFA, VEGFB, LIF, MTOR
41	cellular response to hypoxia	GO:071456	13.2	SFRP1, VLDLR, VHL, VEGFA, LMNA, BMP7
42	response to ethanol	GO:045471	12.9	BGLAP, BCL2, BAK1, FYN, CDK1, MMP9
43	positive regulation of protein kinase B signaling cascade	GO:051897	12.6	PIK3CG, VEGFB, MTOR, MST1R, INS, INSR
44	MAPK cascade	GO:000165	12.5	MYC, RAF1, PAK1, CDK1, INS, FGF8
45	cellular response to mechanical stimulus	GO:071260	12.2	SFTPB, CHEK1, BAD, BAK1, CD40, ITGB1
46	activation of MAPKK activity	GO:000186	11.5	KISS1R, RAF1, JAK2, MAP3K7, MAP2K2, MAP3K13
47	negative regulation of transcription, DNA-dependent	GO:045892	INF	ZNF217, SFRP1, GCLC, RB1, BRCA1, BRMS1
48	negative regulation of cell proliferation	GO:008285	INF	KISS1R, SFN, SFRP1, SFRP4, BTG2, RBM5
49	positive regulation of apoptotic process	GO:043065	INF	SFRP1, SFRP4, RBM5, LPAR1, BMP2, RARG
50	negative regulation of transcription from RNA polymerase II promoter	GO:000122	INF	ZNF202, NCOA2, NCOR1, PCGF2, RBBP8, VLDLR

Molecular functions related to breast carcinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	ATP binding	GO:005524	26.2	PIKFYVE, PIK3CA, PIK3CG, KIT, KIF1B, VRK2
2	protein homodimerization activity	GO:042803	19.6	KIT, VWF, VEGFA, VEGFB, BMP2, BIRC5
3	identical protein binding	GO:042802	18.5	SH3GL2, CNTN2, SFRP1, PCNA, VIM, RAD51
4	protein kinase binding	GO:019901	17.7	RB1CC1, VIM, LIPE, PAK1, BCL2L1, CHEK2
5	protein heterodimerization activity	GO:046982	17.2	BRAF, VEGFA, VEGFB, BOK, MYC, BMP2
6	receptor binding	GO:005102	17.1	SELPLG, SERPINE1, BMP2, RARA, LIF, BCAP31
7	transcription factor binding	GO:008134	16.9	RB1, NBN, VHL, LMO4, MYC, RARA
8	enzyme binding	GO:019899	16.7	BRCA1, VHL, RARA, RAC1, BLZF1, BIRC5
9	growth factor activity	GO:008083	16.5	KITLG, BTC, VEGFA, VEGFB, VEGFC, BMP2
10	transcription regulatory region DNA binding	GO:044212	14.2	ZNF217, NCOR1, BRCA1, PAX2, JUN, FOS
11	heparin binding	GO:008201	13.7	LRPAP1, VTN, SFRP1, SELP, VEGFA, VEGFB
12	cytokine activity	GO:005125	12.8	KITLG, VEGFA, BMP2, BMP6, BMP7, LIF
13	sequence-specific DNA binding	GO:043565	INF	VDR, MYC, RARG, RARA, RARB, ZGPAT
14	protein binding	GO:005515	INF	ZNF217, PIKFYVE, PIK3CA, PIK3R1, PIK3CG, LRP1
15	sequence-specific DNA binding transcription factor activity	GO:003700	INF	ZNF217, ZNF202, PCGF2, RB1, VDR, LMO4